Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1796057

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1796057

Zoonotic Disease Treatment

PUBLISHED:
PAGES: 479 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Zoonotic Disease Treatment Market to Reach US$58.4 Billion by 2030

The global market for Zoonotic Disease Treatment estimated at US$42.9 Billion in the year 2024, is expected to reach US$58.4 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Rabies Disease, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$24.3 Billion by the end of the analysis period. Growth in the Lyme Disease segment is estimated at 5.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.7 Billion While China is Forecast to Grow at 8.5% CAGR

The Zoonotic Disease Treatment market in the U.S. is estimated at US$11.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$11.8 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Zoonotic Disease Treatment Market - Key Trends & Drivers Summarized

Why Is the Focus on Zoonotic Disease Treatment Intensifying in Global Health Strategies?

The urgency surrounding zoonotic disease treatment is intensifying as global health systems contend with the increasing frequency and severity of disease outbreaks originating from animals. Zoonotic diseases, which are transmitted between animals and humans, include a broad spectrum of viral, bacterial, parasitic, and fungal infections such as rabies, avian influenza, anthrax, and more recently, COVID-19. These diseases pose a significant threat not only to human health but also to food security, wildlife conservation, and economic stability. As urbanization expands into wildlife habitats and global travel becomes more frequent, the risk of zoonotic transmission continues to rise. Public health authorities are recognizing the importance of early diagnosis, swift therapeutic intervention, and long-term control strategies to contain outbreaks and minimize fatalities. The inclusion of zoonotic disease preparedness in national and international health policies, including the One Health approach that integrates human, animal, and environmental health, is helping to align resources and coordinate responses across sectors. Pharmaceutical and biotechnology companies are increasing their investments in the development of broad-spectrum antivirals, novel antibiotics, and immunotherapies tailored for zoonotic infections. As awareness grows about the interconnectedness of ecosystems and disease emergence, the focus on effective treatment is becoming central to global epidemic preparedness and response.

How Are Therapeutic Innovations Shaping the Future of Zoonotic Disease Treatment?

Advancements in medical science and biotechnology are playing a pivotal role in enhancing the diagnosis, treatment, and prevention of zoonotic diseases. Novel therapeutic modalities, such as monoclonal antibodies, RNA-based vaccines, and next-generation antivirals, are showing promising results against high-risk pathogens that have historically lacked targeted treatments. Researchers are leveraging genomic sequencing and molecular diagnostics to rapidly identify disease-causing organisms and their resistance profiles, allowing for the customization of treatment regimens. Vaccine development has been revolutionized by mRNA platforms, which offer faster development timelines and scalability in the event of outbreaks. Meanwhile, improvements in drug delivery systems, such as nanoparticle carriers and intranasal formulations, are enhancing the efficacy of therapeutics while reducing side effects. Point-of-care diagnostic tools are enabling quicker clinical decisions, especially in remote or resource-limited settings where zoonotic diseases often emerge. Artificial intelligence and data analytics are being employed to model disease spread and predict future outbreaks, guiding the deployment of medical resources. Innovations in veterinary medicine, including animal vaccines and prophylactic treatments, are also contributing to human health by reducing the initial transmission vectors. These therapeutic advancements are creating a more proactive and responsive framework for managing zoonotic diseases, ensuring that treatments can keep pace with evolving pathogens and cross-species transmission dynamics.

Which Sectors and Stakeholders Are Driving Demand for Zoonotic Disease Treatment Solutions?

The demand for zoonotic disease treatment is expanding across multiple sectors, fueled by the collective efforts of public health authorities, private industry, international agencies, and the agricultural community. Healthcare providers are on the frontline of diagnosing and managing these diseases, necessitating access to effective treatment protocols and up-to-date training. Governments and public health organizations are investing in outbreak response systems, stockpiles of essential medicines, and cross-border surveillance programs to mitigate the risk of widespread transmission. The pharmaceutical industry is ramping up research and development to create therapeutics for both known and emerging zoonotic pathogens, often in collaboration with global health entities like the World Health Organization and the Centers for Disease Control and Prevention. The veterinary and animal health sectors play a critical role in preventing zoonotic outbreaks through vaccination programs, livestock management, and early disease detection. In rural and agricultural communities, farmers and livestock handlers require targeted educational and medical support to manage disease risks effectively. Non-governmental organizations and academic institutions are contributing through research, awareness campaigns, and the development of field-deployable treatment solutions. As climate change, habitat disruption, and global trade continue to influence disease dynamics, the collaboration of these diverse stakeholders is essential to ensure timely and effective zoonotic disease treatment across geographies and populations.

What Global Trends and Pressures Are Fueling Growth in the Zoonotic Disease Treatment Market?

The zoonotic disease treatment market is expanding rapidly due to a combination of global health challenges, economic pressures, and increased scientific capability. The growing number of zoonotic outbreaks in recent decades, including Ebola, Zika, SARS, MERS, and COVID-19, has underscored the necessity of building more resilient health systems with robust diagnostic and therapeutic capacity. Heightened awareness of the economic toll of pandemics is prompting governments and international organizations to prioritize funding for treatment development and pandemic preparedness. Urban encroachment into natural habitats, increased human-animal interactions, and climate change are accelerating the emergence of novel zoonotic pathogens, driving demand for a wide spectrum of therapeutic solutions. Rising global travel and migration amplify the speed and reach of outbreaks, requiring fast and scalable treatment responses. Technological breakthroughs in drug discovery, such as AI-assisted screening and in-silico modeling, are reducing development timelines and enabling the creation of adaptable therapies. The growing recognition of the One Health framework is also leading to more integrated investments that address zoonotic diseases at the intersection of human, animal, and environmental health. Market expansion is further supported by public-private partnerships, international grants, and policy-driven incentives that encourage innovation in neglected and emerging infectious diseases. As a result, the treatment landscape for zoonotic diseases is evolving rapidly, fueled by the urgency to prevent future pandemics and protect global health security.

SCOPE OF STUDY:

The report analyzes the Zoonotic Disease Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease (Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus, Other Diseases); Treatment (Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment, Immunoglobulins Treatment, Antibacterial Medication Treatment, Other Treatments); Administration Route (Intravenous Administration, Intramuscular Administration, Oral Administration); End-User (Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AstraZeneca plc
  • Bayer AG
  • BioCryst Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • CSL Behring
  • Elanco Animal Health Incorporated
  • Eli Lilly and Company
  • F.?Hoffmann-La Roche Ltd. (Roche)
  • GlaxoSmithKline plc (GSK)
  • Hikma Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zoetis Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP39531

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Zoonotic Disease Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Frequency of Zoonotic Outbreaks Throws the Spotlight on Urgent Therapeutic Development
    • Global Health Security Concerns Spur Growth in Investment Toward Zoonotic Disease Treatment R&D
    • Expansion of One Health Initiatives Strengthens the Business Case for Integrated Human-Animal Disease Management
    • Climate Change and Habitat Encroachment Expand Addressable Risk Zones for Emerging Zoonoses
    • Increased Cross-Border Movement and Global Trade Drive Adoption of Scalable and Rapid Response Treatments
    • Antimicrobial Resistance Challenges Propel Innovation in Broad-Spectrum and Targeted Therapies
    • Technological Advancements in Genomics and Pathogen Surveillance Accelerate Drug Discovery for Zoonotic Threats
    • Veterinary-Human Health Convergence Opens Opportunities for Dual-Use Therapeutic Platforms
    • Growing Zoonotic Threats from Wildlife and Livestock Highlight the Need for Early-Stage Diagnostic-Linked Treatments
    • mRNA and Platform-Based Vaccine Technologies Generate Momentum for Rapid-Response Treatment Modalities
    • Increased Use of AI and Predictive Modeling Supports Development of Adaptive and Variant-Ready Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Zoonotic Disease Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Zoonotic Disease Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Zoonotic Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Rabies Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Rabies Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Rabies Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Lyme Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Lyme Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Lyme Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Zika Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Zika Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Zika Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for West Nile Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for West Nile Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for West Nile Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Antibacterial Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Antibacterial Medication Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Antibacterial Medication Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Vaccines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Vaccines Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Vaccines Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Antiviral Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Antiviral Drugs Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: World 16-Year Perspective for Antiviral Drugs Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Antibiotics Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: World 16-Year Perspective for Antibiotics Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Immunoglobulins Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Immunoglobulins Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: World 16-Year Perspective for Immunoglobulins Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Intravenous Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: World 16-Year Perspective for Intravenous Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Intramuscular Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Intramuscular Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: World 16-Year Perspective for Intramuscular Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 48: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 50: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: World Historic Review for Ambulatory Surgery Centers End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: World 16-Year Perspective for Ambulatory Surgery Centers End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 53: World Recent Past, Current & Future Analysis for Homecare Settings End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: World Historic Review for Homecare Settings End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: World 16-Year Perspective for Homecare Settings End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 56: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 59: USA Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: USA Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: USA 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 62: USA Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: USA Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: USA 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: USA Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: USA Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: USA 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 68: USA Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: USA Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: USA 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 71: Canada Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Canada Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Canada 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 74: Canada Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Canada Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Canada 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: Canada Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Canada Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Canada 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 80: Canada Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Canada Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Canada 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • JAPAN
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 83: Japan Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Japan Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Japan 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 86: Japan Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Japan Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Japan 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Japan Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Japan Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Japan 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 92: Japan Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Japan Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Japan 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • CHINA
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 95: China Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: China Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: China 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 98: China Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: China Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: China 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 101: China Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: China Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: China 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 104: China Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: China Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: China 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • EUROPE
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Zoonotic Disease Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Europe 16-Year Perspective for Zoonotic Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 110: Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Europe Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Europe 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 113: Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Europe Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Europe 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Europe Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Europe 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 119: Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Europe Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: Europe 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • FRANCE
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 122: France Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: France Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: France 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 125: France Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: France Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: France 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: France Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: France Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: France 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 131: France Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: France Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: France 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • GERMANY
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 134: Germany Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Germany Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Germany 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 137: Germany Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Germany Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Germany 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 140: Germany Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Germany Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Germany 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 143: Germany Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Germany Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Germany 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 146: Italy Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Italy Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Italy 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 149: Italy Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Italy Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Italy 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 152: Italy Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Italy Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Italy 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 155: Italy Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Italy Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Italy 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 158: UK Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: UK Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: UK 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 161: UK Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: UK Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: UK 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 164: UK Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: UK Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: UK 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 167: UK Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: UK Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: UK 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 170: Spain Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Spain Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Spain 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 173: Spain Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Spain Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Spain 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Spain Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Spain Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Spain 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 179: Spain Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Spain Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Spain 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 182: Russia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Russia Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Russia 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 185: Russia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Russia Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Russia 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Russia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Russia Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Russia 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 191: Russia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Russia Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Russia 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Europe Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Europe 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Europe Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Europe 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Europe Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Europe 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Europe Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Europe 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 207: Asia-Pacific Historic Review for Zoonotic Disease Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Asia-Pacific Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Asia-Pacific Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Asia-Pacific Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 217: Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Asia-Pacific Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 220: Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 221: Australia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Australia Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 223: Australia 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 224: Australia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Australia Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 226: Australia 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 227: Australia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Australia Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 229: Australia 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 230: Australia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Australia Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 232: Australia 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • INDIA
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 233: India Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: India Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 235: India 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 236: India Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: India Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 238: India 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 239: India Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: India Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 241: India 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 242: India Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: India Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 244: India 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 245: South Korea Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: South Korea Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 247: South Korea 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 248: South Korea Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: South Korea Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 250: South Korea 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 251: South Korea Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: South Korea Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 253: South Korea 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 254: South Korea Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: South Korea Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 256: South Korea 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Rest of Asia-Pacific Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 259: Rest of Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Rest of Asia-Pacific Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 262: Rest of Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Rest of Asia-Pacific Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 265: Rest of Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Rest of Asia-Pacific Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 268: Rest of Asia-Pacific 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 269: Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 270: Latin America Historic Review for Zoonotic Disease Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 271: Latin America 16-Year Perspective for Zoonotic Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 272: Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Latin America Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 274: Latin America 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 275: Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Latin America Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 277: Latin America 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 278: Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Latin America Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 280: Latin America 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 281: Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Latin America Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 283: Latin America 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 284: Argentina Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Argentina Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 286: Argentina 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 287: Argentina Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Argentina Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 289: Argentina 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 290: Argentina Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Argentina Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 292: Argentina 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 293: Argentina Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Argentina Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 295: Argentina 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 296: Brazil Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Brazil Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 298: Brazil 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 299: Brazil Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Brazil Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 301: Brazil 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 302: Brazil Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Brazil Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 304: Brazil 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 305: Brazil Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Brazil Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 307: Brazil 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 308: Mexico Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Mexico Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 310: Mexico 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 311: Mexico Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Mexico Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 313: Mexico 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 314: Mexico Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Mexico Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 316: Mexico 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 317: Mexico Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Mexico Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 319: Mexico 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Rest of Latin America Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 322: Rest of Latin America 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Rest of Latin America Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 325: Rest of Latin America 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Rest of Latin America Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 328: Rest of Latin America 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Rest of Latin America Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 331: Rest of Latin America 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 332: Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 333: Middle East Historic Review for Zoonotic Disease Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 334: Middle East 16-Year Perspective for Zoonotic Disease Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 335: Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Middle East Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 337: Middle East 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 338: Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Middle East Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 340: Middle East 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 341: Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Middle East Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 343: Middle East 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 344: Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Middle East Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 346: Middle East 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 347: Iran Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Iran Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 349: Iran 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 350: Iran Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Iran Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 352: Iran 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 353: Iran Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Iran Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 355: Iran 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 356: Iran Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: Iran Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 358: Iran 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 359: Israel Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: Israel Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 361: Israel 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 362: Israel Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: Israel Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 364: Israel 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 365: Israel Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: Israel Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 367: Israel 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 368: Israel Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Israel Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 370: Israel 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Saudi Arabia Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 373: Saudi Arabia 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Saudi Arabia Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 376: Saudi Arabia 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Saudi Arabia Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 379: Saudi Arabia 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Saudi Arabia Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 382: Saudi Arabia 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 383: UAE Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: UAE Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 385: UAE 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 386: UAE Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: UAE Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 388: UAE 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 389: UAE Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: UAE Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 391: UAE 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 392: UAE Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 393: UAE Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 394: UAE 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 396: Rest of Middle East Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 397: Rest of Middle East 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 399: Rest of Middle East Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 400: Rest of Middle East 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 402: Rest of Middle East Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 403: Rest of Middle East 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 405: Rest of Middle East Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 406: Rest of Middle East 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030
  • AFRICA
    • Zoonotic Disease Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 407: Africa Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 408: Africa Historic Review for Zoonotic Disease Treatment by Disease - Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 409: Africa 16-Year Perspective for Zoonotic Disease Treatment by Disease - Percentage Breakdown of Value Sales for Rabies Disease, Lyme Disease, Zika Virus, West Nile Virus and Other Diseases for the Years 2014, 2025 & 2030
    • TABLE 410: Africa Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 411: Africa Historic Review for Zoonotic Disease Treatment by Treatment - Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 412: Africa 16-Year Perspective for Zoonotic Disease Treatment by Treatment - Percentage Breakdown of Value Sales for Antibacterial Medication Treatment, Other Treatments, Vaccines Treatment, Antiviral Drugs Treatment, Antibiotics Treatment and Immunoglobulins Treatment for the Years 2014, 2025 & 2030
    • TABLE 413: Africa Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 414: Africa Historic Review for Zoonotic Disease Treatment by Administration Route - Intravenous Administration, Intramuscular Administration and Oral Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 415: Africa 16-Year Perspective for Zoonotic Disease Treatment by Administration Route - Percentage Breakdown of Value Sales for Intravenous Administration, Intramuscular Administration and Oral Administration for the Years 2014, 2025 & 2030
    • TABLE 416: Africa Recent Past, Current & Future Analysis for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 417: Africa Historic Review for Zoonotic Disease Treatment by End-user - Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 418: Africa 16-Year Perspective for Zoonotic Disease Treatment by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Ambulatory Surgery Centers End-User, Homecare Settings End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!